PCSK6 in Cardiovascular Biology and Disease: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Sirius Huang and Version 1 by Qingyu Wu.

Proprotein convertase subtilisin/kexin 6 (PCSK6) is a secreted serine protease expressed in most major organs, where it cleaves a wide range of growth factors, signaling molecules, peptide hormones, proteolytic enzymes, and adhesion proteins. In the cardiovascular system, PCSK6 acts as a key modulator in heart formation, lipoprotein metabolism, body fluid homeostasis, cardiac repair, and vascular remodeling. To date, dysregulated PCSK6 expression or function has been implicated in major cardiovascular diseases.

  • atrial septal defect
  • cardiac aging
  • corin
  • endothelial lipase
  • hypertension
  • PACE4
  • PCSK6
  • vascular remodeling

1. Introduction

Proteolytic cleavage is a key mechanism in regulating protein structure and function. The proprotein convertase subtilisin/kexin (PCSK) family consists of nine proteolytic enzymes that process a variety of proteins, including peptide hormones, growth factors, cell receptors, proteases, and adhesion molecules [1,2][1][2]. The PCSK-mediated pathways are essential for tissue homeostasis and physiological function. PCSKs are also exploited by pathogens to boost their infectivity. In COVID-19, for example, PCSK-mediated cleavage of spike protein on the surface of severe acute respiratory syndrome (SARS) coronavirus-2 particles is a crucial step for viral entry in human airways [3,4][3][4].
PCSK6, also known as paired basic amino acid cleaving enzyme 4 (PACE4) or subtilisin-like proprotein convertase 4 (SPC4), is a member of the PCSK family. PCSK6-mediated protein cleavage has been implicated in diverse biological processes, ranging from embryonic development to tissue senescence. Human genetic and animal model studies in recent years indicate that PCSK6 is an important regulator in cardiovascular biology and disease.

2. PCSK6 Gene and Tissue Expression

PCSK6 was identified from human hepatoma cells based on sequence similarities to other subtilisin-like proteases [5]. The human PCSK6 gene is located on chromosome 15 at q26.3, with 23 exons in a locus spanning ~228 kb [6]. PCSK6 orthologues are conserved in all vertebrates from fish to primates, an indication of functional significance. PCSK6 mRNA expression has been detected in virtually all major organs, including the brain, heart, lung, liver, spleen, pancreas, kidney, skeletal muscle, uterus, ovary, and placenta [7]. Within the heart, high levels of PCSK6 mRNA are expressed in atrial and ventricular cardiomyocytes [8]. Based on proteomic analysis of human tissues, PCSK6 is also expressed in cardiac fibroblasts, endothelial cells, and smooth muscle cells (SMCs) [9]. It remains unclear if PCSK6 cleaves similar sets of proteins in different cardiac cell types. In addition to normal tissues, upregulated PCSK6 expression has been found in many cancers, including lung cancer [10[10][11],11], breast cancer [12[12][13],13], prostate cancer [14[14][15],15], skin cancer [16,17][16][17], ovarian cancer [18[18][19],19], and thyroid cancer [20]. To date, PCSK6-mediated cleavage of metalloproteinases [17[17][21],21], signaling molecules [22[22][23],23], and apoptotic proteins [23,24][23][24] has been reported as a potential mechanism in tumor invasion and migration. In animal cancer models, PCSK6 inhibitors have been shown to inhibit tumor progression, indicating that PCSK6 is a potential cancer target [16,25,26][16][25][26]. The following discussions focus on the role of PCSK6 in cardiovascular biology. More information on PCSK6 and cancers can be found in several comprehensive reviews [27,28,29][27][28][29].

3. PCSK6 and Cardiovascular Pathophysiology

3.1. Atrial Septal Defects

Atrial septal defects are a common form of congenital heart disease [85][30]. As discussed earlier, Pcsk6 KO mice exhibit a plethora of cardiac abnormalities, including common atrium, double-outlet right ventricle, ventricular septal defects, persistent truncus arteriosus, and dextrocardia [65][31]. Common atrium is a severe type of atrial septal defect, in which the entire atrial septum is missing. In mice, Nodal and Bmp4 are downstream effectors of Pcsk6 in heart formation [65,66][31][32]. However, the upstream molecular network that regulates PCSK6 expression in developing hearts is not well defined. TBX5, NKX2-5, and GATA4 are major transcription factors in heart development. Deleterious TBX5, NKX2-5, and GATA4 mutations are found in individuals with congenital heart disease, including atrial septal defects [86,87][33][34]. Protein odd-skipped-related 1 (OSR1) is a zinc-finger transcription factor, essential for cardiac progenitor growth and atrial septum formation [88][35]. In mouse embryonic hearts, Tbx5 is an immediate Osr1 upstream gene in the second heart field for atrial septation [89][36]. Osr1 deletion results in common atrium and embryonic death between E11.5 and E12.5 days [90][37]. The similar phenotype of atrial septal defects in Tbx5-, Osr1-, and Pcsk6-deficient mice suggests a possible TBX5-OSR1-PCSK6 pathway in promoting TGFβ-like growth factor signaling in atrial septum formation. In agreement with this hypothesis, gene profiling in Tbx5- and Osr1-deficient embryos identifies Pcsk6 as one of the major genes in atrial septation regulated by Tbx5 and Osr1 [91][38]. Human genome-wide linkage analysis also suggests a connection between PCSK6 and congenital heart disease [92][39]. Moreover, a PCSK6 variant is found in a Spanish family with atrial septal defects and interatrial septal aneurysm [91][38]. These findings indicate that TBX5 and OSR1 are possible regulators in PCSK6 expression during heart development, providing new insights into the genetic mechanisms underlying atrial septal defects.

3.2. Endothelial Lipase Inactivation

Endothelial lipase, a member of the triglyceride lipase family, is a secreted protein, consisting of a signal peptide, a 40 kDa N-terminal catalytic domain, and a 28 kDa C-terminal domain [93][40]. Upon secretion, endothelial lipase binds to heparan sulfate proteoglycans on the cell surface, where it hydrolyzes triglycerides and phospholipids in plasma lipoproteins [94][41]. In addition to endothelial cells, endothelial lipase is expressed in hepatocytes, macrophages, and SMCs. Endothelial lipase modifies high-density lipoprotein (HDL) structure and metabolism, as indicated by high levels of plasma HDL cholesterol, bigger HDL particle sizes, and slower HDL clearance in endothelial lipase-deficient mice [95,96][42][43]. Conversely, plasma HDL cholesterol levels are decreased in endothelial lipase overexpressing mice [96,97][43][44]. In humans, deleterious variants in the LIPG gene, encoding endothelial lipase, are associated with increased plasma HDL cholesterol levels [98,99,100][45][46][47]. In membrane-bound serine proteases, ectodomain cleavage is a common mechanism in limiting protease activity on the cell surface [101,102][48][49]. A comparable mechanism exists in endothelial lipase inactivation on the cell surface. In the conditioned medium from human endothelial cells, a 40 kDa endothelial lipase fragment was detected [46,97][44][50]. A similar fragment was also found from human liver HepG2 cell culture [103][51]. As revealed by biochemical analyses, the fragment is derived by cleavage at a specific site, RNKR↓, which reduces the endothelial lipase activity [46,103][50][51]. Furin, PC5A, and PCSK6 are likely responsible for the cleavage [46,103][50][51]. Interestingly, lipoprotein lipase, another member of the triglyceride lipase family, contains an analogous site, RAKR↓, which is also cleaved by furin, PC5A, and PCSK6 in similar experiments [46][50]. These data indicate that PCSK-mediated endothelial lipase inactivation is a cellular mechanism in regulating lipoprotein metabolism. Consistently, hepatic overexpression of pro-furin, an inhibitor of furin, PCSK5, and PCSK6 reduce endothelial lipase inactivation and lower plasma HDL cholesterol in mice [104][52]. In Lipg KO mice, such an effect of pro-furin on plasma HDL cholesterol is not observed, supporting a PCSK-endothelial lipase-dependent mechanism in HDL metabolism. Studies in those mice also validate a role of PCSK-mediated activation of an endogenous endothelial lipase inhibitor, angiopoietin-like 3 [104,105][52][53]. Further analyses in hepatocyte-specific Furin and Pcsk5 conditional KO and Pcsk6 global KO mice show that hepatic furin is primarily responsible for cleavage of endothelial lipase and angiopoietin-like 3 in vivo [106][54]. However, plasma levels of HDL cholesterol are only slightly reduced in the hepatocyte Furin conditional KO mice or not changed in the hepatocyte Pcsk5 conditional and Pcsk6 global KO mice, compared to that in WT mice [106][54]. These findings suggest functional redundancy among PCSKs in endothelial lipase inactivation, at least in mice.

3.3. Corin Activation and Hypertension

Atrial and B-type natriuretic peptides (ANP and BNP, respectively) are hormones in the natriuretic peptide system that preserves body fluid balance and cardiovascular homeostasis [107][55]. Genetic studies in mice and humans establish ANP as a key factor in blood pressure regulation [108,109,110][56][57][58]. Upon binding to its receptor, natriuretic peptide receptor A (also called guanylate cyclase A), ANP enhances renal salt excretion and relaxes blood vessels, thereby lowering blood volume and pressure. Variants in the NPPA gene, encoding ANP, are associated with increased risks of cardiovascular disease, such as hypertension, stroke, and heart disease [111,112][59][60]. Corin is a membrane-bound protease, highly expressed in the heart [113][61], where it converts pro-ANP to ANP [114,115,116][62][63][64]. Like most proteases, corin is produced in a pro-form, which is activated at a specific site, RMNKR↓ [117][65]. The cleavage sequence with paired basic residues indicates that corin is likely activated by one of the PCSKs. Indeed, PCSK6 has been identified as the corin activator [53][66]. Both PCSK6 and corin are expressed in cardiomyocytes, where PCSK6 activates corin on the cell surface [53,118][66][67]. In cultured murine cardiomyocytes, blocking Pcsk6 expression prevents corin activation [53][66]. In Pcsk6-deficient mice, corin activation and pro-ANP processing in the heart are eliminated [53][66]. Like Corin KO mice, Pcsk6-deficient mice develop salt-sensitive hypertension [53[66][68],119], indicating that PCSK6 is the corin activator in vivo and that this function cannot be substituted by other PCSKs. In line with these findings, genetic studies support a role of PCSK6 in corin activation and cardiovascular function in humans. For example, several CORIN variants identified in hypertensive patients are defective in PCSK6-mediated activation [53,120][66][69]. PCSK6 variants are associated with hypertension [53,120][66][69] and coronary artery stenosis [121][70]. Studies in humans and rat models also indicate an important PCSK6-corin-ANP pathway in regulating renal aquaporin 2 and β-epithelial sodium channel expression in response to a high-salt diet [122][71], consistent with salt-sensitive hypertension in Pcsk6, Corin, and Nppa KO mice [53,109,119,123][57][66][68][72]. Moreover, reduced cardiac and renal PCSK6 and corin expression correlates with worsening cardiac and renal function in a rat heart failure model [124][73]. These data highlight the importance of PCSK6 in corin activation and body fluid-electrolyte homeostasis.

3.4. Vascular Remodeling in Atherosclerosis

Atherosclerosis is a major vascular disease, characterized by the formation of atherosclerotic plaques in the intima of medium- to large-sized arteries [125][74]. Depending on disease stages, the plaque usually contains lipid-packed macrophages, also called foam cells, and SMCs that are surrounded by accumulated extracellular matrix proteins and proteoglycans [125][74]. As the disease progresses, the macrophages and SMCs undergo apoptosis, creating a highly thrombotic necrotic core that is prone to rupture, thereby causing thrombosis formation [125][74]. To date, several lines of evidence point to a potential role of PCSK6 in regulating SMC migration, vascular remodeling, and atherosclerotic plaque formation. In patients with aortic dissections in a Korean population, for example, genomic alternations are found in a locus where the PCSK6 gene is located [126][75]. Genome-wide expression analysis indicates elevated PCSK6 expression in atherosclerotic plaques [127,128][76][77]. In cultured human monocytes and endothelial cells, PCSK6 expression and activity are increased by pro-atherogenic lipid oxidation products [129][78]. In Pcsk6 KO mice, compromised vascular remodeling, as indicated by enlarged systolic and diastolic circumferences and reduced contractile SMC markers, is observed in carotid arteries exposed to increased blood flow [130][79]. Increased PCSK6 expression is also detected in smooth muscle α-actin (SMA) (an SMC marker) -positive cells in unstable carotid plaques, where inflammation and extracellular matrix degradation are active [131][80]. Moreover, PCSK6 expression in cultured human carotid SMCs is increased by proinflammatory factors, such as tumor necrosis factor and interferon-γ [131][80]. These findings suggest a connection between PCSK6 and SMC-derived cells in the vessel wall where inflammation and pathological remodeling occur. Consistently, a recent human study links a PCSK6 variant with SMA-positive cell numbers in carotid stenosis lesions and artery wall thickness [132][81]. In human and rodent carotid arteries, increased PCSK6 expression correlates with SMC activation, intimal hyperplasia, and MMP2/MMP14 activation [132][81]. Conversely, decreased intimal hyperplasia and MMP14 activation are found in Pcsk6 KO mice with carotid artery ligation [132][81]. Moreover, aortic SMCs from Pcsk6 KO mice exhibit poor proliferation and migration induced by platelet-derived growth factor BB (PGDFBB), whereas in human SMCs overexpressing PCSK6, PDGFBB-stimulated cell proliferation and migration are increased [132][81]. PCSK6 is known to activate MMPs in cancers [133][82]. The latest findings suggest that PCSK6-mediated MMP activation may be important in SMC phenotypic changes and pathological vascular remodeling in atherosclerosis.

3.5. Cardiac Repair after Myocardial Infarction (MI)

MI triggers a series of cellular events, including cell death, inflammatory cell infiltration, and gradual wound healing with myofibroblast proliferation and ultimate scar formation [134][83]. Tissue remodeling depends on the interplay among various cell types, including immune cells, cardiomyocytes, fibroblasts, and vascular cells. Both autocrine and paracrine mechanisms are involved in cell–cell interactions in infarcted hearts [134][83]. Many serine proteases have been implicated in cardiac structure and function [135][84]. In a recent study, PCSK6 was identified as one of the highly secreted proteins from hypoxic cardiomyocytes [136][85]. The finding is confirmed in mouse hearts undergoing coronary artery ligation [136][85]. The PCSK6 expression and secretion in hypoxic cardiomyocytes promote TGFβ secretion from the same cells and subsequent SMAD (small and mothers against decapentapletic) signaling in cardiac fibroblasts [136][85]. Moreover, high levels of collagen I production and fibrosis-related gene expression (e.g., Col1a1, Col3a1, and Mmp14) are observed in cardiac fibroblasts treated with the PCSK6-containing conditioned medium from hypoxic cardiomyocytes [136][85]. These findings suggest that upregulated PCSK6 in ischemic cardiomyocytes activates TGFβ, which, in turn, binds to its receptor on cardiac fibroblasts, thereby enhancing downstream SMAD signaling to promote collagen production and cardiac fibrosis [136][85]. Increased fibrosis is a hallmark of poor cardiac remodeling, which impairs cardiac function. Consistently, PCSK6 overexpression in cardiomyocytes increases cardiac hypertrophy and fibrosis and decreases cardiac function in a mouse MI model [136][85]. Moreover, increased serum PCSK6 levels are observed in patients with acute MI, which peaks on day 3 post incidence [136][85]. Previously, increased ventricular, but not atrial, Pcsk6 expression was noticed post MI in a rat model [137][86]. These data support a role of PCSK6 in a paracrine mechanism, underlying cardiac remodeling after MI. In another study [138][87], serum PCSK6 levels were associated with cardiovascular events in a subset of patients undergoing coronary angiography. Further studies will be important to evaluate if serum PCSK6 can be used as a biomarker to predict cardiac remodeling and function in patients with heart disease.

3.6. Cardiac Senescence

In aging hearts, altered protein expression and signaling often lead to deteriorating cardiac structure and function. In addition to apoptosis, senescence is a common feature in aging cardiomyocytes, as indicated by DNA damage, dysregulated gene expression, increased oxidative stress, mitochondrial dysfunction, and poor contractility [139,140][88][89]. Natriuretic peptide-mediated signaling is critical in cardiomyocyte homeostasis [111][59]. In humans, variants in the NPPA gene are associated with impaired cardiovascular responsiveness in the elderly [141][90]. In rodents, decreased ANP secretion is found in aging hearts and senescent cardiomyocytes in culture [142,143][91][92]. PCSK6 is necessary for corin activation and ANP generation in the heart [53][66]. A recent study indicates that PCSK6 deficiency may contribute to senescence in cardiomyocytes [144][93]. In aged mouse hearts and senescent cardiomyocytes, Pcsk6 expression is reduced. Moreover, Pcsk6 downregulation causes senescence in cultured cardiomyocytes, as indicated by increased advanced glycation end products, oxidative stress, and apoptosis [144][93]. Conversely, Pcsk6 overexpression prevents senescence and dysfunction in cultured cardiomyocytes under similar experimental conditions [144][93]. The function of PCSK6 in cardiomyocyte senescence appears mediated, at least in part, by pathways related to ER stress. In aging mouse hearts and Pcsk6 knockdown cardiomyocytes, high levels of DNA-damage inducible transcript 3 (Ddit3) are observed [144][93]. Ddit3, also called C/EBP homologous protein, is a pro-apoptotic transcription factor inducted by ER stress [145][94]. In cardiomyocytes subjected to ER stress, Ddit3 expression is suppressed by PCSK6 expression [144][93], suggesting that PCSK6 may regulate cardiomyocyte senescence by reducing ER stress via a DDIT3-related mechanism. Consistent with these findings, increased ER stress is reported in human prostate cancer cells, in which the PCSK6 gene is downregulated [24]. In a mouse model of heart failure, Ddit3 deletion prevents ER-stress-induced cell death and cardiac dysfunction [146][95]. As discussed earlier, premature ovarian senescence is observed in Pcsk6 KO mice [69][96]. It will be important to examine if similar premature aging exists in other major organs in Pcsk6 KO mice.

References

  1. Seidah, N.G.; Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 2012, 11, 367–383.
  2. Shakya, M.; Lindberg, I. Mouse Models of Human Proprotein Convertase Insufficiency. Endocr. Rev. 2021, 42, 259–294.
  3. Seidah, N.G.; Pasquato, A.; Andréo, U. How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread? Viruses 2021, 13, 1229.
  4. Jackson, C.B.; Farzan, M.; Chen, B.; Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022, 23, 3–20.
  5. Kiefer, M.C.; Tucker, J.E.; Joh, R.; Landsberg, K.E.; Saltman, D.; Barr, P.J. Identification of a second human subtilisin-like protease gene in the fes/fps region of chromosome 15. DNA Cell Biol. 1991, 10, 757–769.
  6. Tsuji, A.; Hine, C.; Tamai, Y.; Yonemoto, K.; Yoshida, S.; Bando, M.; Sakai, E.; Mori, K.; Akamatsu, T.; Matsuda, Y. Genomic organization and alternative splicing of human PACE4 (SPC4), kexin-like processing endoprotease. J. Biochem. 1997, 122, 438–452.
  7. Karlsson, M.; Zhang, C.; Méar, L.; Zhong, W.; Digre, A.; Katona, B.; Sjöstedt, E.; Butler, L.; Odeberg, J.; Dusart, P.; et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 2021, 7, eabh2169.
  8. Beaubien, G.; Schäfer, M.K.; Weihe, E.; Dong, W.; Chrétien, M.; Seidah, N.G.; Day, R. The distinct gene expression of the pro-hormone convertases in the rat heart suggests potential substrates. Cell Tissue Res. 1995, 279, 539–549.
  9. Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347, 1260419.
  10. Mbikay, M.; Sirois, F.; Yao, J.; Seidah, N.G.; Chrétien, M. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br. J. Cancer 1997, 75, 1509–1514.
  11. Lin, Y.E.; Wu, Q.N.; Lin, X.D.; Li, G.Q.; Zhang, Y.J. Expression of paired basic amino acid-cleaving enzyme 4 (PACE4) correlated with prognosis in non-small cell lung cancer (NSCLC) patients. J. Thorac. Dis. 2015, 7, 850–860.
  12. Patel, A.; García-Closas, M.; Olshan, A.F.; Perou, C.M.; Troester, M.A.; Love, M.I.; Bhattacharya, A. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2022, 82, 25–35.
  13. Panet, F.; Couture, F.; Kwiatkowska, A.; Desjardins, R.; Guérin, B.; Day, R. PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression. Eur. J. Cell Biol. 2017, 96, 469–475.
  14. Couture, F.; Wang, L.; Dufour, F.; Chabot-Maheux, K.; Ekindi Ndongo, N.; Sabbagh, R.; Day, R. PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer. Sci. Rep. 2022, 12, 6066.
  15. Bakrania, A.; Aubé, M.; Desjardins, R.; Sabbagh, R.; Day, R. Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors. Can. J. Physiol. Pharmacol. 2020, 98, 477–481.
  16. Weishaupt, C.; Mastrofrancesco, A.; Metze, D.; Kemper, B.; Stegemann, A.; Picardo, M.; Klein-Szanto, A.J.; Böhm, M. Paired Basic Amino Acid-cleaving Enzyme 4 (PCSK6): An Emerging New Target Molecule in Human Melanoma. Acta Derm. Venereol. 2020, 100, adv00157.
  17. Bassi, D.E.; Lopez De Cicco, R.; Cenna, J.; Litwin, S.; Cukierman, E.; Klein-Szanto, A.J. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res. 2005, 65, 7310–7319.
  18. Chen, J.; Li, Y.; Wu, J.; Liu, Y.; Kang, S. Whole-exome sequencing reveals potential germline and somatic mutations in 60 malignant ovarian germ cell tumors. Biol. Reprod. 2021, 105, 164–178.
  19. Longuespée, R.; Couture, F.; Levesque, C.; Kwiatkowska, A.; Desjardins, R.; Gagnon, S.; Vergara, D.; Maffia, M.; Fournier, I.; Salzet, M.; et al. Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl. Oncol. 2014, 7, 410–419.
  20. Fradet, L.; Temmar, R.; Couture, F.; Belzile, M.; Fortier, P.H.; Day, R. Evaluation of PACE4 isoforms as biomarkers in thyroid cancer. J. Otolaryngol. Head Neck Surg. 2018, 47, 63.
  21. Lapierre, M.; Siegfried, G.; Scamuffa, N.; Bontemps, Y.; Calvo, F.; Seidah, N.G.; Khatib, A.M. Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells’ malignant phenotypes: Role of tissue inhibitors of metalloproteinase-1. Cancer Res. 2007, 67, 9030–9034.
  22. Wang, P.; Wang, F.; Wang, L.; Pan, J. Proprotein convertase subtilisin/kexin type 6 activates the extracellular signal-regulated kinase 1/2 and Wnt family member 3A pathways and promotes in vitro proliferation, migration and invasion of breast cancer MDA-MB-231 cells. Oncol. Lett. 2018, 16, 145–150.
  23. Tian, X.F.; Huang, G.M.; Zang, H.L.; Cao, H. PACE4 regulates apoptosis in human pancreatic cancer Panc-1 cells via the mitochondrial signaling pathway. Mol. Med. Rep. 2016, 14, 5205–5210.
  24. Guo, H.; Yao, Z.; Sun, B.; Hong, Q.; Yan, J.; Mu, D.; Li, J.; Sheng, H. PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways. Drug Des. Dev. Ther. 2015, 9, 5911–5923.
  25. Kwiatkowska, A.; Couture, F.; Ait-Mohand, S.; Desjardins, R.; Dory, Y.L.; Guérin, B.; Day, R. Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug. Sci. Rep. 2019, 9, 2118.
  26. Levesque, C.; Couture, F.; Kwiatkowska, A.; Desjardins, R.; Guérin, B.; Neugebauer, W.A.; Day, R. PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation. Oncotarget 2015, 6, 3680–3693.
  27. Bassi, D.E.; Fu, J.; Lopez de Cicco, R.; Klein-Szanto, A.J. Proprotein convertases: "master switches" in the regulation of tumor growth and progression. Mol. Carcinog. 2005, 44, 151–161.
  28. Klein-Szanto, A.J.; Bassi, D.E. Proprotein convertase inhibition: Paralyzing the cell’s master switches. Biochem. Pharmacol. 2017, 140, 8–15.
  29. Rose, M.; Duhamel, M.; Rodet, F.; Salzet, M. The Role of Proprotein Convertases in the Regulation of the Function of Immune Cells in the Oncoimmune Response. Front. Immunol. 2021, 12, 667850.
  30. Prica, M.; Kamalathasan, S.; Gopaul, K.; Warriner, D. Adult congenital heart disease: A review of the simple lesions. Br. J. Hosp. Med. 2022, 83, 1–12.
  31. Constam, D.B.; Robertson, E.J. SPC4/PACE4 regulates a TGFbeta signaling network during axis formation. Genes Dev. 2000, 14, 1146–1155.
  32. Beck, S.; Le Good, J.A.; Guzman, M.; Ben Haim, N.; Roy, K.; Beermann, F.; Constam, D.B. Extraembryonic proteases regulate Nodal signalling during gastrulation. Nat. Cell Biol. 2002, 4, 981–985.
  33. Webb, G.; Gatzoulis, M.A. Atrial septal defects in the adult: Recent progress and overview. Circulation 2006, 114, 1645–1653.
  34. McCulley, D.J.; Black, B.L. Transcription factor pathways and congenital heart disease. Curr. Top. Dev. Biol. 2012, 100, 253–277.
  35. Zhou, L.; Liu, J.; Olson, P.; Zhang, K.; Wynne, J.; Xie, L. Tbx5 and Osr1 interact to regulate posterior second heart field cell cycle progression for cardiac septation. J. Mol. Cell. Cardiol. 2015, 85, 1–12.
  36. Xie, L.; Hoffmann, A.D.; Burnicka-Turek, O.; Friedland-Little, J.M.; Zhang, K.; Moskowitz, I.P. Tbx5-hedgehog molecular networks are essential in the second heart field for atrial septation. Dev. Cell 2012, 23, 280–291.
  37. Wang, Q.; Lan, Y.; Cho, E.S.; Maltby, K.M.; Jiang, R. Odd-skipped related 1 (Odd 1) is an essential regulator of heart and urogenital development. Dev. Biol. 2005, 288, 582–594.
  38. Zhang, K.K.; Xiang, M.; Zhou, L.; Liu, J.; Curry, N.; Heine Suner, D.; Garcia-Pavia, P.; Zhang, X.; Wang, Q.; Xie, L. Gene network and familial analyses uncover a gene network involving Tbx5/Osr1/Pcsk6 interaction in the second heart field for atrial septation. Hum. Mol. Genet. 2016, 25, 1140–1151.
  39. Flaquer, A.; Baumbach, C.; Piñero, E.; Algas, F.G.; Sanchez, M.A.D.L.F.; Rosell, J.; Toquero, J.; Alonso-Pulpon, L.; Garcia-Pavia, P.; Strauch, K.; et al. Genome-wide linkage analysis of congenital heart defects using MOD score analysis identifies two novel loci. BMC Genet. 2013, 14, 44.
  40. Rader, D.J.; Jaye, M. Endothelial lipase: A new member of the triglyceride lipase gene family. Curr. Opin. Lipidol. 2000, 11, 141–147.
  41. Khetarpal, S.A.; Vitali, C.; Levin, M.G.; Klarin, D.; Park, J.; Pampana, A.; Millar, J.S.; Kuwano, T.; Sugasini, D.; Subbaiah, P.V.; et al. Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins. PLoS Genet. 2021, 17, e1009802.
  42. Ma, K.; Cilingiroglu, M.; Otvos, J.D.; Ballantyne, C.M.; Marian, A.J.; Chan, L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc. Natl. Acad. Sci. USA 2003, 100, 2748–2753.
  43. Ishida, T.; Choi, S.; Kundu, R.K.; Hirata, K.; Rubin, E.M.; Cooper, A.D.; Quertermous, T. Endothelial lipase is a major determinant of HDL level. J. Clin. Investig. 2003, 111, 347–355.
  44. Jaye, M.; Lynch, K.J.; A Krawiec, J.; Marchadier, D.; Maugeais, C.; Doan, K.; South, V.J.; Amin, D.V.; Perrone, M.H.; Rader, D.J. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 1999, 21, 424–428.
  45. Edmondson, A.C.; Brown, R.J.; Kathiresan, S.; Cupples, L.A.; Demissie, S.; Manning, A.K.; Jensen, M.K.; Rimm, E.B.; Wang, J.; Rodrigues, A.; et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J. Clin. Investig. 2009, 119, 1042–1050.
  46. Cole, J.; Blackhurst, D.M.; Solomon, G.A.E.; Ratanjee, B.D.; Benjamin, R.; Marais, A.D. Atherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants. J. Clin. Lipidol. 2021, 15, 142–150.e142.
  47. Pisciotta, L.; Ossoli, A.; Ronca, A.; Garuti, A.; Fresa, R.; Favari, E.; Calabresi, L.; Calandra, S.; Bertolini, S. Plasma HDL pattern, cholesterol efflux and cholesterol loading capacity of serum in carriers of a novel missense variant (Gly176Trp) of endothelial lipase. J. Clin. Lipidol. 2022, in press.
  48. Wang, L.; Zhang, C.; Sun, S.; Chen, Y.; Hu, Y.; Wang, H.; Liu, M.; Dong, N.; Wu, Q. Autoactivation and calpain-1-mediated shedding of hepsin in human hepatoma cells. Biochem. J. 2019, 476, 2355–2369.
  49. Jiang, J.; Wu, S.; Wang, W.; Chen, S.; Peng, J.; Zhang, X.; Wu, Q. Ectodomain shedding and autocleavage of the cardiac membrane protease corin. J. Biol. Chem. 2011, 286, 10066–10072.
  50. Jin, W.; Fuki, I.V.; Seidah, N.G.; Benjannet, S.; Glick, J.M.; Rader, D.J. Proprotein convertases are responsible for proteolysis and inactivation of endothelial lipase. J. Biol. Chem. 2005, 280, 36551–36559.
  51. Gauster, M.; Hrzenjak, A.; Schick, K.; Frank, S. Endothelial lipase is inactivated upon cleavage by the members of the proprotein convertase family. J. Lipid Res. 2005, 46, 977–987.
  52. Jin, W.; Wang, X.; Millar, J.S.; Quertermous, T.; Rothblat, G.H.; Glick, J.M.; Rader, D.J. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 2007, 6, 129–136.
  53. Hato, T.; Tabata, M.; Oike, Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc. Med. 2008, 18, 6–14.
  54. Essalmani, R.; Susan-Resiga, D.; Chamberland, A.; Asselin, M.-C.; Canuel, M.; Constam, D.; Creemers, J.W.; Day, R.; Gauthier, D.; Prat, A.; et al. Furin is the primary in vivo convertase of angiopoietin-like 3 and endothelial lipase in hepatocytes. J. Biol. Chem. 2013, 288, 26410–26418.
  55. Nishikimi, T.; Kato, J. Cardiac Peptides-Current Physiology, Pathophysiology, Biochemistry, Molecular Biology, and Clinical Application. Biology 2022, 11, 330.
  56. Salo, P.P.; Havulinna, A.S.; Tukiainen, T.; Raitakari, O.; Lehtimäki, T.; Kähönen, M.; Kettunen, J.; Männikkö, M.; Eriksson, J.G.; Jula, A.; et al. Genome-Wide Association Study Implicates Atrial Natriuretic Peptide Rather Than B-Type Natriuretic Peptide in the Regulation of Blood Pressure in the General Population. Circ. Cardiovasc. Genet. 2017, 10, e001713.
  57. John, S.W.; Krege, J.H.; Oliver, P.M.; Hagaman, J.R.; Hodgin, J.B.; Pang, S.C.; Flynn, T.G.; Smithies, O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995, 267, 679–681.
  58. Tamura, N.; Ogawa, Y.; Chusho, H.; Nakamura, K.; Nakao, K.; Suda, M.; Kasahara, M.; Hashimoto, R.; Katsuura, G.; Mukoyama, M.; et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. USA 2000, 97, 4239–4244.
  59. Song, W.; Wang, H.; Wu, Q. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 2015, 569, 1–6.
  60. Rubattu, S.; Forte, M.; Marchitti, S.; Volpe, M. Molecular Implications of Natriuretic Peptides in the Protection from Hypertension and Target Organ Damage Development. Int. J. Mol. Sci. 2019, 20, 798.
  61. Yan, W.; Sheng, N.; Seto, M.; Morser, J.; Wu, Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J. Biol. Chem. 1999, 274, 14926–14935.
  62. Zhang, X.; Gu, X.; Zhang, Y.; Dong, N.; Wu, Q. Corin: A Key Mediator in Sodium Homeostasis, Vascular Remodeling, and Heart Failure. Biology 2022, 11, 717.
  63. Dong, N.; Niu, Y.; Chen, Y.; Sun, S.; Wu, Q. Function and regulation of corin in physiology and disease. Biochem. Soc. Trans. 2020, 48, 1905–1916.
  64. Yan, W.; Wu, F.; Morser, J.; Wu, Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc. Natl. Acad. Sci. USA 2000, 97, 8525–8529.
  65. Knappe, S.; Wu, F.; Masikat, M.R.; Morser, J.; Wu, Q. Functional analysis of the transmembrane domain and activation cleavage of human corin: Design and characterization of a soluble corin. J. Biol. Chem. 2003, 278, 52363–52370.
  66. Chen, S.; Cao, P.; Dong, N.; Peng, J.; Zhang, C.; Wang, H.; Zhou, T.; Yang, J.; Zhang, Y.; Martelli, E.E.; et al. PCSK6-mediated corin activation is essential for normal blood pressure. Nat. Med. 2015, 21, 1048–1053.
  67. Chen, S.; Wang, H.; Li, H.; Zhang, Y.; Wu, Q. Functional analysis of corin protein domains required for PCSK6-mediated activation. Int. J. Biochem. Cell Biol. 2018, 94, 31–39.
  68. Wang, W.; Shen, J.; Cui, Y.; Jiang, J.; Chen, S.; Peng, J.; Wu, Q. Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. Kidney Int. 2012, 82, 26–33.
  69. Zhang, Y.; Zhou, T.; Niu, Y.; He, M.; Wang, C.; Liu, M.; Yang, J.; Zhang, Y.; Zhou, J.; Fukuda, K.; et al. Identification and functional analysis of CORIN variants in hypertensive patients. Hum. Mutat. 2017, 38, 1700–1710.
  70. Wakim, V.; Abi Khalil, E.; Salloum, A.K.; Khazen, G.; Ghassibe-Sabbagh, M.; Zalloua, P.A. New susceptibility alleles associated with severe coronary artery stenosis in the Lebanese population. BMC Med. Genom. 2021, 14, 90.
  71. Zhang, J.; Yin, Y.; Chen, L.; Chu, C.; Wang, Y.; Lv, Y.; He, M.; Martin, M.; Huang, P.-H.; Mu, J.-J.; et al. Short-Term High-Salt Diet Increases Corin Level to Regulate the Salt-Water Balance in Humans and Rodents. Am. J. Hypertens. 2018, 31, 253–260.
  72. Chan, J.C.; Knudson, O.; Wu, F.; Morser, J.; Dole, W.P.; Wu, Q. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc. Natl. Acad. Sci. USA 2005, 102, 785–790.
  73. Khoury, E.E.; Fokra, A.; Kinaneh, S.; Knaney, Y.; Aronson, D.; Abassi, Z. Distribution of Cardiac and Renal Corin and Proprotein Convertase Subtilisin/Kexin-6 in the Experimental Model of Cardio-Renal Syndrome of Various Severities. Front. Physiol. 2021, 12, 673497.
  74. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473, 317–325.
  75. Suh, J.H.; Yoon, J.S.; Kwon, J.B.; Kim, H.W.; Wang, Y.P. Identification of genomic aberrations by array comparative genomic hybridization in patients with aortic dissections. Korean J. Thorac. Cardiovasc. Surg. 2011, 44, 123–130.
  76. Turpeinen, H.; Raitoharju, E.; Oksanen, A.; Oksala, N.; Levula, M.; Lyytikäinen, L.-P.; Järvinen, O.; Creemers, J.W.; Kähönen, M.; Laaksonen, R.; et al. Proprotein convertases in human atherosclerotic plaques: The overexpression of FURIN and its substrate cytokines BAFF and APRIL. Atherosclerosis 2011, 219, 799–806.
  77. Suur, B.E.; Chemaly, M.; Liljeqvist, M.L.; Djordjevic, D.; Stenemo, M.; Bergman, O.; Karlöf, E.; Lengquist, M.; Odeberg, J.; Hurt-Camejo, E.; et al. Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease. Front. Pharmacol. 2022, 13, 988561.
  78. Testa, G.; Staurenghi, E.; Giannelli, S.; Sottero, B.; Gargiulo, S.; Poli, G.; Gamba, P.; Leonarduzzi, G. Up-regulation of PCSK6 by lipid oxidation products: A possible role in atherosclerosis. Biochimie 2021, 181, 191–203.
  79. Röhl, S.; Suur, B.E.; Lengquist, M.; Seime, T.; Caidahl, K.; Hedin, U.; Arner, A.; Matic, L.; Razuvaev, A. Lack of PCSK6 Increases Flow-Mediated Outward Arterial Remodeling in Mice. Cells 2020, 9, 1009.
  80. Perisic, L.; Hedin, E.; Razuvaev, A.; Lengquist, M.; Osterholm, C.; Folkersen, L.; Gillgren, P.; Paulsson-Berne, G.; Ponten, F.; Odeberg, J.; et al. Profiling of atherosclerotic lesions by gene and tissue microarrays reveals PCSK6 as a novel protease in unstable carotid atherosclerosis. Arter. Thromb. Vasc. Biol. 2013, 33, 2432–2443.
  81. Rykaczewska, U.; Suur, B.E.; Röhl, S.; Razuvaev, A.; Lengquist, M.; Sabater-Lleal, M.; van der Laan, S.W.; Miller, C.L.; Wirka, R.C.; Kronqvist, M.; et al. PCSK6 Is a Key Protease in the Control of Smooth Muscle Cell Function in Vascular Remodeling. Circ. Res. 2020, 126, 571–585.
  82. Bassi, D.E.; Mahloogi, H.; Klein-Szanto, A.J. The proprotein convertases furin and PACE4 play a significant role in tumor progression. Mol. Carcinog. 2000, 28, 63–69.
  83. Prabhu, S.D.; Frangogiannis, N.G. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ. Res. 2016, 119, 91–112.
  84. Wu, Q.; Kuo, H.C.; Deng, G.G. Serine proteases and cardiac function. Biochim. Biophys. Acta 2005, 1751, 82–94.
  85. Kuhn, T.C.; Knobel, J.; Burkert-Rettenmaier, S.; Li, X.; Meyer, I.S.; Jungmann, A.; Sicklinger, F.; Backs, J.; Lasitschka, F.; Müller, O.J.; et al. Secretome Analysis of Cardiomyocytes Identifies PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6) as a Novel Player in Cardiac Remodeling After Myocardial Infarction. Circulation 2020, 141, 1628–1644.
  86. Sawada, Y.; Inoue, M.; Kanda, T.; Sakamaki, T.; Tanaka, S.; Minamino, N.; Nagai, R.; Takeuchi, T. Co-elevation of brain natriuretic peptide and proprotein-processing endoprotease furin after myocardial infarction in rats. FEBS Lett. 1997, 400, 177–182.
  87. Yang, S.F.; Chou, R.H.; Lin, S.J.; Li, S.Y.; Huang, P.H. Serum PCSK6 and corin levels are not associated with cardiovascular outcomes in patients undergoing coronary angiography. PLoS ONE 2019, 14, e0226129.
  88. Nakou, E.S.; Parthenakis, F.I.; Kallergis, E.M.; Marketou, M.E.; Nakos, K.S.; Vardas, P.E. Healthy aging and myocardium: A complicated process with various effects in cardiac structure and physiology. Int. J. Cardiol. 2016, 209, 167–175.
  89. Bernhard, D.; Laufer, G. The aging cardiomyocyte: A mini-review. Gerontology 2008, 54, 24–31.
  90. Iemitsu, M.; Maeda, S.; Otsuki, T.; Sugawara, J.; Kuno, S.; Ajisaka, R.; Matsuda, M. Arterial stiffness, physical activity, and atrial natriuretic Peptide gene polymorphism in older subjects. Hypertens. Res. 2008, 31, 767–774.
  91. Pollack, J.A.; Skvorak, J.P.; Nazian, S.J.; Landon, C.S.; Dietz, J.R. Alterations in atrial natriuretic peptide (ANP) secretion and renal effects in aging. J. Gerontol. A Biol. Sci. Med. Sci. 1997, 52, B196–B202.
  92. Häseli, S.; Deubel, S.; Jung, T.; Grune, T.; Ott, C. Cardiomyocyte Contractility and Autophagy in a Premature Senescence Model of Cardiac Aging. Oxidative Med. Cell. Longev. 2020, 2020, 8141307.
  93. Zhan, W.; Chen, L.; Liu, H.; Long, C.; Liu, J.; Ding, S.; Wu, Q.; Chen, S. Pcsk6 Deficiency Promotes Cardiomyocyte Senescence by Modulating Ddit3-Mediated ER Stress. Genes 2022, 13, 711.
  94. Marciniak, S.J.; Yun, C.Y.; Oyadomari, S.; Novoa, I.; Zhang, Y.; Jungreis, R.; Nagata, K.; Harding, H.P.; Ron, D. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004, 18, 3066–3077.
  95. Fu, H.Y.; Okada, K.-I.; Liao, Y.; Tsukamoto, O.; Isomura, T.; Asai, M.; Sawada, T.; Okuda, K.; Asano, Y.; Sanada, S.; et al. Ablation of C/EBP homologous protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac dysfunction induced by pressure overload. Circulation 2010, 122, 361–369.
  96. Mujoomdar, M.L.; Hogan, L.M.; Parlow, A.F.; Nachtigal, M.W. Pcsk6 mutant mice exhibit progressive loss of ovarian function, altered gene expression, and formation of ovarian pathology. Reproduction 2011, 141, 343–355.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback